Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Talk overview
- Classifying immune-mediated rheumatic diseases
- Scope of this talk
- Global prevalence is increasing
- Autoantibody versus cell mediated
- Genetics and environmental factors
- Autoimmune diseases have a strong genetic component
- Genome-wide (GWAS) association studies
- GWAS in rheumatoid arthritis
- Role for MHC-II-mediated CD4 T cell activation
- Interaction of genetics with the environment
- From risk genes to pathogenic antibodies
- Classification of autoantibody-mediated diseases
- GWAS in ankylosing spondylitis
- Central role for HLA-B27 in spondyloarthritidies
- From GWAS to function in spondyloarthritis
- Key immune pathways
- Macrophages are key effectors
- A role for distinct fibroblast subsets in joint disease
- TNF blockade and treating rheumatic diseases
- Multiple pathways can be targeted for the treatment of rheumatoid arthritis
- Type 17 pathway is important in seronegative spondyloarthritidies
- Expanded Th17 compartment
- IL-17A has multiple effector functions
- The enthesis
- Theories for pathogenesis of ankylosing spondylitis
- Future perspectives
- The role of the microbiome
- The era of single cell
- Thank you
Topics Covered
- Classifying immune-mediated rheumatic diseases
- Rheumatoid arthritis
- The influence of genetics and environmental factors on rheumatic diseases
- Ankylosing spondylitis
- Key immune pathways involved in the pathogenesis of rheumatic diseases
- Evidence for the role of the microbiome in shaping the immune response
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Al-Mossawi, H. (2021, December 12). The immunology underlying rheumatic diseases [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/IFQB7279.Export Citation (RIS)
Publication History
Financial Disclosures
- I am now a full time employee of AstraZeneca, where I work in the respiratory and immunology late-stage clinical development team. None of the research or therapies mentioned in the talk are related in any way to AstraZeneca.
Other Talks in the Series: The Immune System - Key Concepts and Questions
Transcript
Please wait while the transcript is being prepared...
0:00
My name is Hussein Al-Mossawi.
I'm a fellow and lecturer of medicine at St. Edmund Hall at the University of Oxford.
Today I'm going to be describing the immunology
underlying rheumatic inflammatory diseases.
0:14
The way I've structured this talk is to think about four key areas.
Firstly, the framework for the classification of immune-mediated rheumatic diseases.
Then secondly, we're going to focus on the interplay
between role of the genetics and environmental factors.
Thirdly, we'll consider some of
the key immune pathways that have been successfully targeted for therapeutic benefit,
and then we'll take a future perspective to look at technologies and
platforms coming through that will help inform us
and better our understanding of these diseases.
0:50
Now we're going to focus on the framework for
classifying immune-mediated rheumatic diseases.
0:57
Broadly speaking immune-mediated rheumatic diseases
can be thought of in three groups.
You have the biggest group and the best described rheumatic immune-mediated disease,
which is rheumatoid arthritis.
This is a destructive immune-mediated
inflammatory arthritis that affects predominantly the small joints of the hands.
It can affect multiple other systems in the body.
Some features of rheumatoid arthritis overlap with
autoimmune connective tissue diseases including systemic lupus erythematosus,
systemic sclerosis and inflammatory myopathies.
These diseases are multisystem in nature and can affect multiple organs.
They're characterised by specific autoantibody profiles that drive the pathology.
The connective tissue diseases can overlap with
rheumatoid arthritis and share this feature of autoantibody involvement.
In the red, you can see a group of
diseases that we call the seronegative spondyloarthropathies.
These diseases are not characterised by the presence of an autoantibody.
They include diseases such as ankylosing spondylitis,
psoriatic arthritis and enteropathic arthritis which is
associated with inflammatory bowel diseases such as Crohn's and ulcerative colitis.